Ono Pharmaceutical, Co., Ltd. has completed the tender offer to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. for USD 25.60 per share (total amount of approximately USD 2.4 billion) net to the seller in cash, through its wholly owned subsidiary, Topaz Merger Sub, Inc.

Following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned subsidiary of Ono. In connection with the acquisition, Deciphera shares ceased to be traded on Nasdaq as of the date of closing of the acquisition and shares of Deciphera’s common stock will be delisted from Nasdaq.

“We are very pleased to welcome Deciphera into the family. Through this acquisition, we will leverage Deciphera's excellent research and development capabilities in the oncology field and its sales power in Europe and the United States, and work to further accelerate the expansion of our pipeline and global expansion, which are part of our growth strategies,” said Gyo Sagara, Chairman and CEO of Ono.

"We are excited to enter a new phase as part of the family of Ono Pharmaceuticals, which has as its mission to contribute to society through the discovery and development of innovative drugs, under the corporate philosophy “Dedicated to the Fight against Disease and Pain,” said Steven L. Hoerter, President and CEO of Deciphera.

“By fully leveraging the research and development capabilities and commercialization platforms of both companies, we look forward to significantly contributing to the growth of the Ono Group as a global specialty pharma company,” Hoerter added.